Suppr超能文献

青光眼的药物递送系统:叙述性综述

Drug Delivery Systems for Glaucoma: A Narrative Review.

作者信息

Fea Antonio M, Vallino Veronica, Cossu Michela, Marica Valentina, Novarese Cristina, Reibaldi Michele, Petrillo Francesco

机构信息

Department of Ophthalmology, "City of Health and Science" Hospital, 10126 Turin, Italy.

出版信息

Pharmaceuticals (Basel). 2024 Sep 2;17(9):1163. doi: 10.3390/ph17091163.

Abstract

Glaucoma is one of the world's leading causes of blindness, and its management is challenging. The main objective is to lower intraocular pressure through medical, para-surgical, and surgical therapy. Medical therapy often represents the first line of treatment. Although effective in many cases, the eye drops are accompanied by significant problems. They require high patient compliance and can be associated with various side effects, limiting their efficacy. Consequently, the research for new drug delivery systems trying to overcome these limitations is ongoing: numerous devices are developing and gradually entering clinical practice. These new therapeutic options may offer better control of the intraocular pressure, with fewer side effects, and are less dependent on patients' compliance. Hence, the research in this field continues to flourish. This review summarizes the most recent findings in the scientific literature, underlines the role and possible limitations of the new glaucoma drug delivery systems in clinical practice, and recognizes their new horizons and perspectives.

摘要

青光眼是全球主要的致盲原因之一,其治疗颇具挑战性。主要目标是通过药物、准手术和手术治疗来降低眼压。药物治疗通常是一线治疗方法。尽管眼药水在许多情况下有效,但也伴随着诸多问题。它们需要患者高度依从,并且可能伴有各种副作用,从而限制了其疗效。因此,旨在克服这些局限性的新型药物递送系统的研究正在进行中:众多设备正在研发并逐渐进入临床实践。这些新的治疗选择可能能更好地控制眼压,副作用更少,且对患者依从性的依赖更小。因此,该领域的研究持续蓬勃发展。本综述总结了科学文献中的最新发现,强调了新型青光眼药物递送系统在临床实践中的作用及可能存在的局限性,并认识到它们的新前景和新视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8cd/11435076/215b394dd25c/pharmaceuticals-17-01163-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验